NPI 1366606923: Open Payments
NPI 1366606923. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$188 in 9 payments from 8 companies in 2025. Trend: 2023 $104 · 2024 $53 · 2025 $188
Food & beverage: $188
| Company | Payments | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 2 | $44 |
| Novo Nordisk Inc | 1 | $29 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| Alkermes, Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $18 |
| Exact Sciences Corporation | 1 | $16 |
Products named: INVEGA SUSTENNA, Ozempic, INGREZZA, ARISTADA, Belbuca, ABILIFY ASIMTUFII, CAPLYTA, Cologuard Collection Kit.
